Working… Menu
Trial record 1 of 10 for:    X4P
Previous Study | Return to List | Next Study

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma (X4P-001-MELA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02823405
Recruitment Status : Completed
First Posted : July 6, 2016
Last Update Posted : July 7, 2020
Information provided by (Responsible Party):
X4 Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 15, 2018
Actual Study Completion Date : March 15, 2018